(S)-Warfarin
| Code | Size | Price |
|---|
| TAR-T19708-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
(S)-Warfarin is a more effective enantiomer of Warfarin. It is used as a vitamin K antagonist, with anticoagulant.
CAS:
5543-57-7
Formula:
C19H16O4
Molecular Weight:
308.333
Purity:
0.98
SMILES:
CC(=O)C[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O
References
1. Seecheran R, Seecheran V, Persad S, Seecheran NA. Rivaroxaban as an Antithrombotic Agent in a Patient With ST-Segment Elevation Myocardial Infarction and Left Ventricular Thrombus: A Case Report. J Investig Med High Impact Case Rep. 2017 Mar 23;5(1):2324709617697991. doi: 10.1177/2324709617697991. eCollection 2017 Jan-Mar. PubMed PMID: 28540312; PubMed Central PMCID: PMC5433551.
2. Deitelzweig S, Luo X, Gupta K, Trocio J, Mardekian J, Curtice T, Lingohr-Smith M, Menges B, Lin J. Comparison of Effectiveness and Safety of Treatment with Apixaban vs. Other Oral Anticoagulants Among Elderly Nonvalvular Atrial Fibrillation Patients. Curr Med Res Opin. 2017 May 23:1-25. doi: 10.1080/03007995.2017.1334638. [Epub ahead of print] PubMed PMID: 28535119.
3. Asim M, Al-Thani H, El-Menyar A. Recurrent Deep Vein Thrombosis After the First Venous Thromboembolism Event: A Single-Institution Experience. Med Sci Monit. 2017 May 20;23:2391-2399. PubMed PMID: 28527240.
4. Verdecchia P, Reboldi G, Angeli F, Mazzotta G, Lip GYH, Brueckmann M, Kleine E, Wallentin L, Ezekowitz MD, Yusuf S, Connolly SJ, Di Pasquale G. Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study. Europace. 2017 May 17. doi: 10.1093/europace/eux022. [Epub ahead of print] PubMed PMID: 28520924.